Diabetes mellitus is a risk factor for the development of gastroparesis. Currently, metoclopramide is the only US FDA-approved medication for the treatment of gastroparesis. However, the FDA ...

The exact mechanism of action of metoclopramide in the treatment of gastroesophageal reflux and acute and recurrent diabetic gastroparesis has not been fully established. It seems to sensitize ...

GIMOTI® (metoclopramide) nasal spray remains the sole FDA-approved treatment for diabetic gastroparesis, providing effective symptom relief and substantial cost savings compared to oral ...

As the sole FDA-approved nasal spray treatment for acute and recurrent diabetic gastroparesis in adults, GIMOTI® (metoclopramide) is uniquely positioned to address the ongoing needs of patients ...

NEW YORK, Nov. 26, 2024 /PRNewswire/ -- Report with market evolution powered by AI - The global gastroparesis drugs market size is estimated to grow by USD 1.42 billion from ...

Metoclopramide is used for the symptomatic treatment of post-operative or chemotherapy-induced nausea and vomiting, gastroesophageal reflux disease and gastroparesis. Metoclopramide is generally ...